当前位置: 首页 >> 检索结果
97. Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.
作者: Hairong Xu.;Xiaohui Niu.;Vinod Ravi.;Javier Martin-Broto.;Albiruni Abdul Razak.;Ramy Saleh.;Yong Zhou.;Jingnan Shen.;Tang Liu.;Kamlesh Kumar Sankhala.;César Serrano.;Silvia Stacchiotti.;Jing Wang.;Giacomo G Baldi.;Yi Feng.;Yingqi Hua.;Tao Li.;Piotr Rutkowski.;Xiaojing Zhang.;Gabriel Tinoco.;Qingping Zou.;Boyao Shan.;Xiangyu Zhu.;Hans Gelderblom.
来源: Lancet. 2026年407卷10533期1072-1083页
Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm that affects otherwise healthy adults. There are few systemic treatment options, highlighting an unmet need. We report the results of part 1 of the MANEUVER trial, which aimed to evaluate the efficacy and safety of pimicotinib, a highly selective, potent, colony-stimulating factor-1 receptor inhibitor, in patients with TGCT.
100. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial.
作者: Michel Azizi.;Jenifer M Brown.;Jamie P Dwyer.;John M Flack.;Erica S W Jones.;Raisa Kurlyandskaya.;Hongjian Li.;Filip Birve.;Aina S Lihn.;Shira Perl.;Markus P Schlaich.;Hirotaka Shibata.;Ji-Guang Wang.;Bryan Williams.; .
来源: Lancet. 2026年407卷10532期988-999页
Aldosterone dysregulation is an important contributor in the pathogenesis of hard-to-control hypertension. We aimed to assess the effect of baxdrostat, a selective aldosterone synthase inhibitor, on ambulatory blood pressure in patients with resistant hypertension.
|